Click to Share
 
 
  1. Latest News
  2. Submit Press Release
  1. PR Home
  2. Latest News
  3. Feeds
  4. Alerts
  5. Submit Free Press Release
  6. Journalist Account
  7. PRNewswire Distribution

pwrm Press Releases

  + XML/RSS  



By Lynn Lumpkin
Enzo Biochem, Inc. (NYSE:ENZ) reported improved sequential results for the first fiscal quarter ended October 31, 2010, the result of recent programs to reduce expenses, consolidate activities and expand operations.

By Karl McMahon
Power3 Medical Products, Inc. (OTC.BB:PWRM) a leading proteomics company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases,

By Greg Lumpkin
PWRM pursues an aggressive intellectual property strategy to protect its inventions and discoveries made on its own and with its collaborators.

By Blayne Sheffield
PWRM.OB, HMA, RDN, & NVE: NV Energy, Inc. Reports Third Quarter Earnings

By Blayne Sheffield
Power3 has filed several patent applications for its NuroPro® technology that are currently pending. Power3 also has a world-wide exclusive license from the Baylor College of Medicine in Houston, Texas.

By Blayne Sheffield
NRO, ULU, SA, & PWRM.OB: Drills Upgrading Large Resource at Seabridge Gold's Courageous Lake Project

By Hanson
Power3 Medical Products (OTCBB: PWRM.OB) BC-SeraPro™ was developed and its performance characteristics determined by the Power3 Medical Products Laboratories.

By Hanson
PWRM BC-SeraPro was developed and its performance characteristics determined by the Power3 Medical Products Laboratories.BC-SeraPro™ is an ideal diagnostic test to evaluate breast cancer abnormalities

By Hanson
Power3 Medical Products (OTCBB: PWRM.OB) BC-SeraPro™ was developed and its performance characteristics determined by the Power3 Medical Products Laboratories.

By Hanson
With these results, PWRM’s NuroPro now extends into the pharmaceutical arena due to its ability to predict and monitor the response to drug treatment

By Blayne Sheffield
PWRM.OB, ILMN, & VSYM.OB: ILMN has recently reported the production of the Eco Real-Time PCR System

By Hanson
The Company is in a strong competitive position with over 190 identified biomarkers and a state-of-the-art proteomics laboratory.

By Hanson
BC-SeraPro™ could detect the disease at a point when treatment is more effective, less expensive, or both.

By Hanson
PWRM’s NuroPro was originally indicated for diagnostics to determine whether or not a patient had Alzheimer’s disease.

By Blayne Sheffield
PWRM, MNTA, & SNY: Raul E. Kohan will be appointed Chief Executive Officer

By Hanson
Power3 Medical Products Inc., (OTCBB: PWRM.OB) strives to become the premier biotechnology company specializing in the commercialization of proteomics IP for the diagnosis and treatment of disease by using cutting edge technologies

By Blayne Sheffield
MNTA, GENZ, & PWRM.OB: Biotech Stocks: Onyx, Genzyme, Momenta in spotlight

By Blayne Sheffield
GENZ, PWRM, & SNY: Blink on Friday And Miss Massive Biotech Spikes

By Hanson
PWRM’s NuroPro Blood Test is diagnostic tool for the early detection of Neurodegenerative diseases.

By Justin Handy
PWRM recently has unexpectedly discovered new and unprecedented findings regarding clinically important differences in the response of the NuroPro protein biomarkers in the blood of untreated Alzheimer’s disease

By Blayne Sheffield
PWRM, ILMN, & CAH: Sequenom Rises as Ladenburg Says Buy, Jefferies Starts at Hold

By Blayne Sheffield
AFFX, LIFE, & OTC:PWRM: Affymetrix Launches Axiom Custom Genotyping Arrays Utilizing World's Largest Validated SNP Database

By Blayne Sheffield
SNY, GSK, & OTC:PWRM: Weekly Pharma Roundup: GSK Settles, Vivus Disappoints, Ely Lilly Axes

By Blayne Sheffield
Molecular Insight Pharmaceuticals is a clinical-stage biopharmaceutical company and a pioneer in the emerging field of molecular medicine. The Company is focused on the discovery.

By Justin Handy
PWRM continues to evolve and enhance its IP portfolio, employing sensitive and specific combinations of biomarkers it has discovered from a broad range of diseases as the basis of highly selective blood-based tests

By Justin Handy
PWRM.OB is a leader in bio-medical research and the commercialization of neurodegenerative disease and cancer biomarkers, pathways, and mechanisms of diseases through the development of diagnostic tests and drug targets.

By Justin Handy
Power3 Medical Products, Inc. strives to become the premier biotechnology company specializing in the commercialization of proteomics IP for the diagnosis and treatment of disease by using cutting edge technologies.

By Justin Handy
PWRM is a leader in bio-medical research and the commercialization of neurodegenerative disease and cancer biomarkers, pathways, and mechanisms of diseases through the development of diagnostic tests and drug targets.

By Justin Handy
PWRM is now available for $0.038 cents a share with an RSI creeping closer to 30 which could be interpreted as a time to buy. Since the beginning of June 2010 PWRM has been trading in a channel. Pay attention for a possible breakout.

By Blayne Sheffield
Affymetrix GeneChip® microarray technology is the industry-standard tool for analyzing complex genetic information.

By Jensen Handy
BC-SeraPro™ was developed and its performance characteristics determined by the Power3 Medical Products Laboratories.

By crwepicks
PWRM is now available for $0.039 cents a share with an RSI creeping closer to 30 which could be interpreted as a time to buy. Since the beginning of June 2010 PWRM has been trading in a channel.

By Justin Handy
PWRM is a leader in bio-medical research and the commercialization of neurodegenerative disease and cancer biomarkers, pathways, and mechanisms of diseases through the development of diagnostic tests and drug targets.

By Blayne Sheffield
Amgen Inc. is a biotechnology medicines company, discovers, develops, manufactures, and delivers human therapeutics based on advances in cellular and molecular biology primarily in the United States

By crwepicks
Cyclacel's cancer drug gets FDA orphan status: PWRM, SIGA, & CYCC

By crwepicks
Crawford, Molecular Insight Pharmaceuticals: Biggest Price Decliners (CRDB, MIPI)

By Justin Handy
PWRM strives to become the premier biotech company specializing in the commercialization of proteomics IP for the diagnosis and treatment of disease by using cutting edge technology, world class quality procedures and superior research methodologies.

By Justin Handy
PWRM is still available for $0.036 cents a share and is continuing creeping closer to 30 RSI, which could be interpreted as a time to buy. Since the beginning of June 2010 PWRM has been trading in a channel.

By crwepicks
PWRM is now available for $0.04 cents a share with an RSI creeping closer to 30 which could be interpreted as a time to buy. Since the beginning of June 2010 PWRM has been trading in a channel.

By crwepicks
PWRM is now available for $.04 cents a share. Since the beginning of June 2010 PWRM has been trading in a channel. Pay attention for a possible breakout. A breakout could be an indicator of possible momentum.

By crwepicks
The intellectual property that Power3 has and continues to pursue today covers the product areas of breast cancer, neurodegenerative diseases, and drug resistance.

By Justin Handy
PWRM is still available for $0.0375 cents a share and is continuing creeping closer to 30 RSI, which could be interpreted as a time to buy. Since the beginning of June 2010 PWRM has been trading in a channel. Pay attention for a possible breakout.

By crwepicks
Fascinating Breakthroughs In Pharmaceutical Research Companies: PWRM, SIGA, & CYCC

By Arnu Saucedo
DrStockPick.com is pleased to announce its Daily Stocks to Watch!

By crwepicks
NNVC Invading Into VIRL and PWRM’s areas of research

By Arnu Saucedo
DrStockPick.com is pleased to announce its Daily Stocks to Watch!

By Justin Handy
PWRM pursues an aggressive intellectual property strategy to protect its inventions and discoveries made on its own and with its collaborators. Power3 Medical works with key physician scientists at major medical research and treatment centers.

By Jensen Handy
Corgenix Medical Corporation (OTC Bulletin Board: CONX), a worldwide developer and marketer of diagnostic test kits

By crwepicks
Albany Molecular Research Inc. announced today that its board of directors has approved a new share repurchase program of up to $10 million

By Justin Handy
Power 3 Medical Products Inc. (OTC BB: PWRM.OB) recently has filed for 2 patent protection, one on Alzheimer’s disease specific differential diagnosis.



Page:

Page updated every 10 minutes


  1. SiteMap
  2. Contact PRLog
  3. Privacy Policy
  4. Terms of Service
  5. Copyright Notice
  6. About
  7. Advertise
Like PRLog?
9K2K1K
Click to Share